Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Am J Transplant. 2023 Apr 7;23(8):1182–1193. doi: 10.1016/j.ajt.2023.03.025

Figure 1: Treatment schedules for anti-CD154 mAb, TNX-1500 and hu5c8.

Figure 1:

Treatment schedules and dosing regimens for low- (loTNX) and standard-dose (sTNX) maintenance TNX groups are illustrated. An historical hu5c8 regimen is shown for reference.

TNX, TNX-1500; MMF, mycophenolate mofetile; hu5c8, mouse-human IgG1κ chimeric anti-CD154; d, post-transplant days